ArticleScientific reports2025
Pan-cancer analysis reveals immunological and prognostic significance of CCT5 in human tumors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integration of CCT/TRiC assembly, degradation and function: Chaperonin complexity in a cellular context.Cell stress & chaperones · 2026Review
- Decoding the Oncogenic Role of USP22 Through Pan-Cancer Genomic and Epigenetic Analysis.Cancer reports (Hoboken, N.J.) · 2026Article
- Chaperonin in health and disease.Molecular biomedicine · 2026Review
- CCT7 predicts poor prognosis and correlates with immune infiltration in colonic adenocarcinoma.Journal of molecular histology · 2026Article
- Pan-cancer landscape of protein kinase D3: An integrative TCGA multi-omics analysis of clinical, molecular, and immunological roles.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chaperonin containing TCP1 subunit 5 (CCT5) is believed to function as a tumor driver. However, a systematic pan-cancer analysis of CCT5 is still lacking. Therefore, this study aimed to identify the potential role of CCT5 in different types of tumors. This study comprehensively investigated the gene expression, proteomic expression, immune infiltration, DNA methylation, genetic alterations, correlation with TMB and MSI, drug sensitivity, enrichment analysis, and prognostic significance of CCT5 in 33 different tumors based on the TIMER2.0, GEPIA2, UALCAN, SMART, cBioPortal, GSCA databases, and TCGAplot R package. The results revealed significant CCT5 overexpression in most tumors and was significantly associated with poor OS and DFS in different tumor types. Reduced promoter and N-shore methylation of CCT5, indicating its potential oncogenic and epigenetic roles. Amplification was the most common type of CCT5 alterations. Immune infiltration analysis revealed a strong correlation between CCT5 and different immune cells. CCT5 exhibited a significant correlation with TMB and MSI in KIRC and STAD. Furthermore, enrichment analysis revealed associations between CCT5 and cell cycle pathway and various cellular functions. These findings suggested that CCT5 might serve as a potential prognostic biomarker and target for immunotherapy in various cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.